Phenotypic and pharmacogenetic aspects of ovulation induction in WHO II anovulatory women.
Because of an enormous increase in pharmacogenetic and -genomic knowledge, an era of predicting drug response on the basis of one's genome is drawing close to reality. Anovulation is the most common cause of infertility, and outcomes of treatment are often unpredictable. This review aims to summarise in what way genetic variability might modify effects of drug-metabolising enzymes, transporters and receptors, thereby altering response to drugs used in ovulation induction.
Overbeek
Annelies
A
Department of Obstetrics and Gynaecology, Division of Reproductive Medicine, VU University Medical Centre, Amsterdam, The Netherlands. a.overbeek@vumc.nl
Lambalk
Cornelis B
CB
D000858:Anovulation / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D006801:Humans; D010062:Ovulation Induction; D010597:Pharmacogenetics; D010641:Phenotype; D014944:World Health Organization
D005300:Fertility Agents, Female